- Home
- MNSB vs TLSI Comparison
MNSB vs TLSI Comparison
Compare MNSB & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNSB
- TLSI
- Stock Information
- Founded
- MNSB 2003
- TLSI 2010
- Country
- MNSB United States
- TLSI United States
- Employees
- MNSB N/A
- TLSI N/A
- Industry
- MNSB Major Banks
- TLSI Medical Specialities
- Sector
- MNSB Finance
- TLSI Health Care
- Exchange
- MNSB Nasdaq
- TLSI Nasdaq
- Market Cap
- MNSB 149.7M
- TLSI 150.0M
- IPO Year
- MNSB N/A
- TLSI N/A
- Fundamental
- Price
- MNSB $22.79
- TLSI $5.05
- Analyst Decision
- MNSB
- TLSI Strong Buy
- Analyst Count
- MNSB 0
- TLSI 5
- Target Price
- MNSB N/A
- TLSI $10.90
- AVG Volume (30 Days)
- MNSB 16.8K
- TLSI 95.0K
- Earning Date
- MNSB 07-22-2025
- TLSI 08-12-2025
- Dividend Yield
- MNSB 1.76%
- TLSI N/A
- EPS Growth
- MNSB N/A
- TLSI N/A
- EPS
- MNSB N/A
- TLSI N/A
- Revenue
- MNSB $64,604,000.00
- TLSI $35,990,000.00
- Revenue This Year
- MNSB $17.95
- TLSI $55.39
- Revenue Next Year
- MNSB $2.52
- TLSI $54.89
- P/E Ratio
- MNSB N/A
- TLSI N/A
- Revenue Growth
- MNSB N/A
- TLSI 45.50
- 52 Week Low
- MNSB $15.00
- TLSI $3.42
- 52 Week High
- MNSB $22.82
- TLSI $5.88
- Technical
- Relative Strength Index (RSI)
- MNSB 74.68
- TLSI 59.87
- Support Level
- MNSB $19.51
- TLSI $4.17
- Resistance Level
- MNSB $22.00
- TLSI $5.28
- Average True Range (ATR)
- MNSB 0.46
- TLSI 0.46
- MACD
- MNSB 0.15
- TLSI 0.16
- Stochastic Oscillator
- MNSB 98.20
- TLSI 87.63
About MNSB MainStreet Bancshares Inc.
MainStreet Bancshares Inc is a bank holding company. It is focused on serving the borrowing, cash management and depository needs of small to medium-sized businesses, and professional practices and retail customers. The bank's products and services include business and consumer checking, premium interest-bearing checking, business account analysis, savings, certificates of deposit and other depository services, as well as a broad array of commercial, real estate and consumer loans.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.